KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Assets (2016 - 2025)

Historic Assets for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $2.3 billion.

  • CRISPR Therapeutics AG's Assets rose 103.52% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.3 billion, marking a year-over-year increase of 103.52%. This contributed to the annual value of $2.3 billion for FY2025, which is 103.52% up from last year.
  • CRISPR Therapeutics AG's Assets amounted to $2.3 billion in Q4 2025, which was up 103.52% from $2.2 billion recorded in Q3 2025.
  • CRISPR Therapeutics AG's Assets' 5-year high stood at $2.9 billion during Q2 2021, with a 5-year trough of $2.0 billion in Q1 2021.
  • Moreover, its 5-year median value for Assets was $2.3 billion (2024), whereas its average is $2.3 billion.
  • Its Assets has fluctuated over the past 5 years, first soared by 17705.98% in 2021, then plummeted by 1848.99% in 2022.
  • Over the past 5 years, CRISPR Therapeutics AG's Assets (Quarter) stood at $2.8 billion in 2021, then decreased by 18.49% to $2.2 billion in 2022, then dropped by 0.6% to $2.2 billion in 2023, then increased by 0.56% to $2.2 billion in 2024, then grew by 1.04% to $2.3 billion in 2025.
  • Its last three reported values are $2.3 billion in Q4 2025, $2.2 billion for Q3 2025, and $2.0 billion during Q2 2025.